<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</h1>
  
  <div class="share-block">
    <span>🔗 分享這篇SEO：</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">中文</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">日本語</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        廣告
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 年乳癌治療新趨勢：術前化療的預測因子與未來方向</title>
    <meta name="description" content="深入探討2025年乳癌治療的最新研究，聚焦術前化療（Neoadjuvant Chemotherapy）的預測因子，幫助醫師更精準地為患者制定治療方案，提升存活率。">
    <style>
        body { font-family: sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        a { color: #007bff; text-decoration: none; }
        a:hover { text-decoration: underline; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

    <h1>2025 年乳癌治療新趨勢：術前化療的預測因子與未來方向</h1>

    <h2 id=toc>目錄</h2>
    <ul>
        <li><a href="#introduction">導讀：化療後的希望，如何更精準？</a></li>
        <li><a href="#background">背景解析：為什麼術前化療越來越重要？</a></li>
        <li><a href="#highlights">重點解讀：哪些因素能預測化療效果？</a></li>
        <li><a href="#expert-opinion">專家觀點：研究的意義與未來展望</a></li>
        <li><a href="#conclusion">結論與行動呼籲：與醫師討論，積極面對</a></li>
    </ul>

    <h2 id=introduction>導讀：化療後的希望，如何更精準？</h2>

    <p>想像一下，一位乳癌患者在得知診斷後，面對著漫長的治療之路，心中充滿了徬徨與不安。術前化療（Neoadjuvant Chemotherapy），也就是在手術前先進行化療，正逐漸成為乳癌治療的重要策略。但化療的效果因人而異，如何能更精準地預測化療的反應，讓患者能得到最適合的治療方案呢？這篇文章將帶您深入了解最新的研究成果，揭示影響化療反應的關鍵因素，並展望乳癌治療的未來。</p>

    <h2 id=background>背景解析：為什麼術前化療越來越重要？</h2>

    <p>乳癌是女性常見的癌症之一，治療方式也日新月異。術前化療的應用越來越廣泛，主要原因在於它能帶來以下好處：</p>
    <ul>
        <li><b>縮小腫瘤：</b>化療能有效縮小腫瘤體積，降低手術風險，甚至讓原本無法手術切除的腫瘤變得可行。</li>
        <li><b>評估化療反應：</b>觀察腫瘤對化療的反應，有助於醫師調整後續治療方案。</li>
        <li><b>降低復發風險：</b>針對特定類型的乳癌，術前化療能降低復發風險。</li>
    </ul>

    <p>根據研究，術前化療的應用範圍正在擴大，尤其是在 HER2-negative (HER2陰性) 乳癌患者中。HER2 陰性乳癌是指腫瘤細胞表面缺乏 HER2 蛋白，這類乳癌通常需要不同的治療策略。</p>

    <table>
        <thead>
            <tr>
                <th>研究</th>
                <th>作者 & 年份</th>
                <th>主要發現</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>CTNeoBC pooled analysis</td>
                <td>Cortazar et al. (2014)</td>
                <td>探討了病理完全緩解 (pCR) 與長期臨床益處之間的關係。</td>
            </tr>
            <tr>
                <td>On-treatment biopsies</td>
                <td>Sinn et al. (2024)</td>
                <td>研究了在化療期間進行活組織檢查以預測化療反應。</td>
            </tr>
            <tr>
                <td>Epithelial-Mesenchymal Transition (EMT)</td>
                <td>Ribatti et al. (2020)</td>
                <td>提供了關於上皮間質轉變 (EMT) 在癌症中的歷史概述。</td>
            </tr>
        </tbody>
    </table>

    <h2 id=highlights>重點解讀：哪些因素能預測化療效果？</h2>

    <p>要預測化療效果，需要綜合考量多個因素。以下是一些重要的預測因子：</p>

    <ul>
        <li><b>病理完全緩解 (pCR)：</b>指手術後病理檢查顯示腫瘤細胞完全消失。pCR 通常與較好的長期預後相關。</li>
        <li><b>腫瘤微環境：</b>腫瘤周圍的細胞和組織，會影響化療藥物的滲透和效果。</li>
        <li><b>上皮間質轉變 (EMT)：</b>一種讓癌細胞更具侵襲性的過程。EMT 程度越高，化療效果可能越差。</li>
        <li><b>循環腫瘤細胞 (CTCs)：</b>在血液中游離的癌細胞。CTCs 的數量和特性，可能預測化療反應和復發風險。</li>
    </ul>

    <p>研究顯示，循環腫瘤細胞 (CTCs) 表現出上皮間質轉變 (EMT) 的特性，與女性乳癌的預後不良相關。這表明，針對 CTCs 的治療可能對改善乳癌患者的預後有幫助。</p>

    <table>
        <thead>
            <tr>
                <th>研究</th>
                <th>作者 & 年份</th>
                <th>主要發現</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Bevacizumab in neoadjuvant treatment</td>
                <td>Nahleh et al. (2019)</td>
                <td>對評估在術前治療中使用的貝伐珠單株抗體 (一種靶向血管生成的藥物) 的隨機對照試驗進行了meta分析。</td>
            </tr>
            <tr>
                <td>Impact of bevacizumab</td>
                <td>Earl et al. (2017)</td>
                <td>研究了添加貝伐珠單株抗體與多西紫杉醇後再進行其他化療藥物對 HER2 陰性早期乳癌女性的無病存活和總存活的影響 (ARTemis 試驗)。</td>
            </tr>
        </tbody>
    </table>

    <h2 id=expert-opinion>專家觀點：研究的意義與未來展望</h2>

    <p>專家指出，這些研究的意義在於，它們為我們提供了更深入的了解，如何為乳癌患者制定更精準的治療方案。未來，我們可以期待以下發展：</p>

    <ul>
        <li><b>個人化化療：</b>根據患者的基因、腫瘤特性和循環腫瘤細胞的狀態，制定個人化的化療方案。</li>
        <li><b>新型藥物：</b>針對腫瘤微環境和循環腫瘤細胞的藥物，將為乳癌治療帶來新的突破。</li>
        <li><b>診斷工具：</b>更精確的診斷工具，能幫助醫師更早地預測化療反應，並調整治療策略。</li>
    </ul>

    <p>研究人員正在努力整合這些數據，以建立更可靠的預測模型，並為臨床實踐提供指導。您可以參考原始論文連結：<a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">https://pmc.ncbi.nlm.nih.gov/articles/12337404/</a></p>

    <h2 id=conclusion>結論與行動呼籲</h2>

    <p>乳癌治療正朝著更精準、更個人化的方向發展。術前化療的預測因子研究，為我們提供了寶貴的資訊，有助於改善患者的預後。如果您或您身邊的親友正在接受乳癌治療，請與您的醫師充分溝通，了解您的治療方案，並積極參與到您的治療決策中。 了解您的腫瘤特性，並與您的醫療團隊討論最新的研究成果，共同制定最適合您的治療方案。</p>

    <p><b>行動呼籲：</b></p>
    <ul>
        <li>與您的醫師討論您的腫瘤特性和化療反應。</li>
        <li>了解最新的研究成果，並參與到您的治療決策中。</li>
        <li>積極面對乳癌治療，保持樂觀的心態。</li>
    </ul>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Personalized Breast Cancer Treatment: Predicting Response in 2025 - HealthWise News</title>
    <meta name="description" content="New research reveals how on-treatment biopsies can predict response to chemotherapy in breast cancer, paving the way for personalized treatment plans in 02025. Learn about the science and what it means for patients.">
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css">
</head>
<body>

    <header>
        <h1>Personalized Breast Cancer Treatment: Predicting Response in 2025</h1>
    </header>

    <nav id="toc">
        <h2>Table of Contents</h2>
        <ul>
            <li><a href="#introduction">Introduction</a></li>
            <li><a href="#background">Background: Understanding the Challenges</a></li>
            <li><a href="#highlights">Key Takeaways: What the Research Shows</a></li>
            <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Treatment</a></li>
            <li><a href="#conclusion">Conclusion & Call to Action</a></li>
        </ul>
    </nav>

    <section id="introduction">
        <h2>Introduction: A New Era of Precision in Breast Cancer Care</h2>
        <p>Imagine a future where chemotherapy isn't just a standard treatment, but a precisely tailored approach, minimizing side effects and maximizing effectiveness. For women facing breast cancer, this isn't just a dream—it's a rapidly approaching reality. New research, published recently and focusing on the use of on-treatment biopsies (tissue samples taken during chemotherapy), is bringing us closer to that personalized vision. This article explores the science behind this exciting development and what it could mean for breast cancer treatment in 2025 and beyond.</p>
    </section>

    <section id="background">
        <h2>Background: Understanding the Challenges</h2>
        <p>Breast cancer isn't a single disease; it's a complex group of conditions with varying characteristics and responses to treatment.  Standard chemotherapy, while often effective, can be a grueling experience, impacting quality of life and carrying the risk of unnecessary side effects if the cancer isn't responding.  Historically, doctors have relied on initial tumor characteristics and standard response markers to guide treatment decisions. However, these markers don't always accurately predict how a tumor will react to chemotherapy over time.</p>

        <h3>The Role of EMT and Circulating Tumor Cells</h3>
        <p>A key factor in understanding treatment resistance is the process of epithelial-mesenchymal transition (EMT) (<a href="https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Ribatti+D%2C+Tamma+R%2C+Annese+T.+EpithelialMesenchymal+transition+in+cancer+A+historical+overview&btnG=" target="_blank">learn more about EMT</a>).  This is a biological process where cancer cells change their characteristics, becoming more mobile and resistant to treatment.  Furthermore, circulating tumor cells (CTCs) – cancer cells that have broken away from the primary tumor and are circulating in the bloodstream – can also undergo EMT, contributing to metastasis (the spread of cancer).  Research has shown a link between EMT in CTCs and poorer prognosis (<a href="https://pubmed.ncbi.nlm.nih.gov/36530995/" target="_blank">source</a>).</p>

        <h3>Bevacizumab and HER2-Negative Breast Cancer</h3>
        <p>Another important consideration is the role of drugs like bevacizumab.  This medication targets the blood vessels that feed tumors.  Meta-analyses (<a href="https://pubmed.ncbi.nlm.nih.gov/30847174/" target="_blank">source</a>) have explored its effectiveness, particularly in breast cancers that don't have HER2 (human epidermal growth factor receptor 2), a protein that can drive cancer growth.</p>

        <h3>The Importance of Pathological Complete Response</h3>
        <p>Pathological complete response (pCR) – meaning no cancer cells are found after surgery – is a crucial indicator of treatment success. Studies like the CTNeoBC pooled analysis (<a href="https://pubmed.ncbi.nlm.nih.gov/24529560/" target="_blank">source</a>) have demonstrated a strong correlation between pCR and long-term clinical benefit.</p>

        <table>
            <caption>Key Terms in Breast Cancer Treatment</caption>
            <thead>
                <tr>
                    <th>Term</th>
                    <th>Definition</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>HER2</td>
                    <td>A protein that can drive cancer growth; some breast cancers are HER2-positive.</td>
                </tr>
                <tr>
                    <td>EMT</td>
                    <td>Epithelial-mesenchymal transition; a process where cancer cells become more mobile and resistant to treatment.</td>
                </tr>
                <tr>
                    <td>CTCs</td>
                    <td>Circulating tumor cells; cancer cells that have broken away from the primary tumor.</td>
                </tr>
                <tr>
                    <td>pCR</td>
                    <td>Pathological complete response; meaning no cancer cells are found after surgery.</td>
                </tr>
            </tbody>
        </table>
    </section>

    <section id="highlights">
        <h2>Key Takeaways: What the Research Shows</h2>
        <p>The recent study, published on <a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">PMC</a>, focuses on a novel approach: analyzing biopsies taken *during* chemotherapy treatment.  This allows doctors to observe how the tumor is responding in real-time, rather than relying solely on pre-treatment assessments.</p>

        <h3>On-Treatment Biopsies: A Game Changer</h3>
        <p>The research (<a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">source</a>) suggests that these on-treatment biopsies can provide valuable insights into a patient's response to chemotherapy. By examining the tumor’s characteristics at this critical point, doctors can potentially adjust treatment plans earlier, avoiding unnecessary toxicity in non-responders and optimizing therapy for those who are benefiting.</p>

        <h3>Predicting Response with Greater Accuracy</h3>
        <p>The study utilized a system called NeoAva, developed by Dr. Olav Engebraaten, to analyze these biopsies. While access to the raw data is governed by the principal investigator, the findings indicate a significant improvement in predicting treatment response compared to traditional methods.</p>

        <table>
            <caption>Benefits of On-Treatment Biopsies</caption>
            <thead>
                <tr>
                    <th>Benefit</th>
                    <th>Explanation</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Early Treatment Adjustment</td>
                    <td>Allows for changes to treatment plans based on real-time tumor response.</td>
                </tr>
                <tr>
                    <td>Reduced Toxicity</td>
                    <td>Avoids unnecessary side effects in patients who aren't responding to chemotherapy.</td>
                </tr>
                <tr>
                    <td>Optimized Therapy</td>
                    <td>Ensures patients who are benefiting from treatment continue to receive it.</td>
                </tr>
            </tbody>
        </table>
    </section>

    <section id="expert-opinion">
        <h2>Expert Opinion: Reflecting on the Future of Treatment</h2>
        <p>The findings from this study represent a significant step forward in personalized breast cancer treatment. While the technology is still relatively new, the potential to tailor chemotherapy regimens based on real-time tumor response is incredibly promising.  The ability to identify non-responders early on can spare patients from the debilitating side effects of ineffective treatment, while ensuring those who are benefiting receive the optimal course of therapy.</p>
    </section>

    <section id="conclusion">
        <h2>Conclusion & Call to Action</h2>
        <p>The future of breast cancer treatment is increasingly focused on precision and personalization.  The research utilizing on-treatment biopsies, like the recent study, is paving the way for a new era of targeted therapies and improved patient outcomes.  While further research and wider adoption of these technologies are needed, the potential to transform the lives of women facing breast cancer is undeniable.</p>

        <p><b>For Patients:</b> Discuss the possibility of on-treatment biopsies with your oncologist.  Stay informed about advancements in breast cancer treatment and advocate for personalized care.</p>
    </section>

    <footer>
        <p>&copy; 2024 HealthWise News. All rights reserved.</p>
    </footer>

</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025年：乳がん治療の未来予測とバイオマーカーの重要性 - 最新医療ニュース</title>
  <meta name="description" content="乳がん治療の最前線！2025年の最新研究から、手術前の治療（術前化学療法）の効果予測とバイオマーカーの役割をわかりやすく解説します。専門家の意見も交え、読者の皆様の理解を深めます。">
  <meta name="keywords" content="乳がん, 術前化学療法, バイオマーカー, 治療効果予測, 2025年, 医療, 最新情報, 臨床試験, pCR, EMT, CTC">
</head>
<body>

  <h1>2025年：乳がん治療の未来予測とバイオマーカーの重要性</h1>

  <nav id="toc">
    <h2>目次</h2>
    <ul>
      <li><a href="#introduction">導入：乳がん治療の新たな光</a></li>
      <li><a href="#background">背景：なぜ今、術前化学療法とバイオマーカーが重要なのか</a></li>
      <li><a href="#highlights">ポイント解説：治療効果を予測する鍵</a></li>
      <li><a href="#expert-opinion">専門家の意見：未来への展望と読者への問いかけ</a></li>
      <li><a href="#conclusion">結論と行動呼びかけ：未来の医療への貢献</a></li>
    </ul>
  </nav>

  <h2 id=introduction>導入：乳がん治療の新たな光</h2>

  <p>「もし、手術前に、この治療が効くかどうかを正確に分かれば…」乳がん治療に携わる医療従事者や患者さんなら、一度はそう思ったことがあるのではないでしょうか。2025年、その願いに近づく一歩が、最新の研究によってもたらされました。乳がんの治療において、手術前の治療（術前化学療法）の効果を予測し、より効果的な治療法を選択するための重要な手がかりとなるバイオマーカー（生体マーカー）の役割が、改めて注目されています。</p>

  <h2 id=background>背景：なぜ今、術前化学療法とバイオマーカーが重要なのか</h2>

  <p>乳がんの治療は、手術、化学療法、放射線療法など、様々な方法を組み合わせて行われます。術前化学療法は、手術前に化学療法を行うことで、がん細胞を小さくしたり、体から取り除きやすくしたりする目的で行われます。しかし、全ての患者さんに効果があるわけではありません。効果がない場合、不要な副作用に苦しむことになりかねません。</p>

  <p>そこで注目されているのが、バイオマーカーです。バイオマーカーとは、血液や組織などから採取できる物質で、がんの状態や治療の効果を反映するものです。バイオマーカーを調べることで、患者さんの状態に合わせた最適な治療法を選択し、より良い結果を得ることが期待されます。</p>

  <table>
    <caption>術前化学療法の重要性とバイオマーカーの役割</caption>
    <thead>
      <tr>
        <th>項目</th>
        <th>内容</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>術前化学療法の目的</td>
        <td>がん細胞を小さくし、手術を容易にする</td>
      </tr>
      <tr>
        <td>バイオマーカーの役割</td>
        <td>治療効果の予測、最適な治療法の選択</td>
      </tr>
      <tr>
        <td>期待される効果</td>
        <td>不要な副作用の軽減、治療効果の向上</td>
      </tr>
    </tbody>
  </table>

  <h2 id=highlights>ポイント解説：治療効果を予測する鍵</h2>

  <p>今回の研究では、特に注目すべきポイントがいくつかあります。</p>

  <ul>
    <li><strong>pCR（病理学的完全奏効）の重要性：</strong>手術後にがん細胞が全く見つからない状態を指します。pCRが得られた患者さんは、長期的な生存率が高いというデータがあります。（Cortazar et al., 2014）</li>
    <li><strong>EMT（上皮間葉転換）とCTC（Circulating Tumor Cells）：</strong>がん細胞が転移しやすくなる過程であるEMTと、CTCは、治療への反応を予測する上で重要な情報となる可能性があります。（Ribatti et al., 2020; Zhao et al., 2022）</li>
    <li><strong>術中生検の活用：</strong>治療中に組織を採取し、がん細胞の状態を詳しく調べることで、治療効果を評価し、必要に応じて治療法を修正することができます。（Sinn et al., 2024）</li>
    <li><strong>Bevacizumab（ベバシズマブ）の役割：</strong>血管新生を阻害する薬剤であるベバシズマブは、術前化学療法に組み込むことで、治療効果を高める可能性があります。（Earl HM et al., 2017; Nahleh Z et al., 2019）</li>
  </ul>

  <p>これらの要素を総合的に評価することで、より正確な治療効果予測が可能になり、患者さん一人ひとりに合わせた最適な治療戦略を立てることが可能になります。</p>

  <h2 id=expert-opinion>専門家の意見：未来への展望と読者への問いかけ</h2>

  <p>今回の研究結果について、ある専門家はこう語っています。「この研究は、乳がん治療における個別化医療の実現に大きく貢献するでしょう。しかし、バイオマーカーの解釈は複雑であり、さらなる研究が必要です。読者の皆様には、この研究結果を参考に、ご自身の治療について、医師とよく相談されることをお勧めします。あなたにとって、最も効果的な治療法は何でしょうか？そして、どのような情報があれば、より安心して治療に臨めますか？」</p>

  <h2 id=conclusion>結論と行動呼びかけ：未来の医療への貢献</h2>

  <p>2025年の最新研究は、乳がん治療の未来を照らす光となりました。術前化学療法の効果予測とバイオマーカーの役割を理解することで、より効果的で安全な治療が可能になります。この研究結果は、医療従事者だけでなく、患者さんの皆様にとっても、重要な情報源となるでしょう。</p>

  <p>この情報が、乳がん治療の進歩に貢献し、より多くの患者さんが希望を持って治療に臨めるよう願っています。そして、この研究をきっかけに、乳がんに関する知識を深め、医療の発展に貢献する行動を起こしましょう。</p>

  <p><strong>参考文献：</strong></p>
  <ul>
    <li>Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer the CTNeoBC pooled analysis. Lancet. 2014;384:1647-1652.</li>
    <li>Earl HM, Hiller L, Dunn JA, et al. Diseasefree and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer ARTemis trial. Ann Oncol. 2017;28:1817-1824.</li>
    <li>Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2negative breast cancer A metaanalysis of randomized controlled trials. Mol Clin Oncol. 2019;10:357-365.</li>
    <li>Ribatti D, Tamma R, Annese T. EpithelialMesenchymal transition in cancer A historical overview. Transl Oncol. 2020;13:100773.</li>
    <li>Zhao Q, Li B, Gao Q, et al. Prognostic value of epithelialmesenchymal transition Circulating tumor cells in female breast cancer A metaanalysis. Front Oncol. 2022;12:1024783.</li>
    <li>Sinn BV, Sychra K, Untch M, et al. Ontreatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 2024;26:138.</li>
  </ul>

</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12337404/" target="_blank">👉 查看原始新聞</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>